EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma

Julie Williamson iD, Muhammad Zaki Hidayatullah Fadlullah iD, Magdalena Kovacsovics-Bankowski iD, Berit Gibson, Umang Swami iD, Alyssa Erickson-Wayman, Debra Jamison, Dan Sageser, Joanne Jeter, Tawnya L Bowles iD, Donald M Cannon, Ben Haaland und 7 weitere

Current Oncology · 2025

DOI: 10.3390/curroncol32030144 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, 2025. Verfasst von Julie Williamson und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, UT 84112, USA. Hauptthemen laut MEDLINE: Melanoma, Ipilimumab, Temozolomide, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with advanced melanoma who progress on standard-dose ipilimumab (Ipi) + nivolumab continue to have poor prognosis. Studies support a dose–response activity of Ipi, and one promising combination is Ipi 10 mg/kg (Ipi10) + temozolomide (TMZ). We performed a retrospective cohort analysis of patients with advanced melanoma treated with Ipi10 + TMZ in the immunotherapy refractory/resistant setting (n = 6, all progressed after prior Ipi + nivolumab), using similar patients treated with Ipi3 + TMZ (n = 6) as comparison. Molecular profiling by whole-exome sequencing (WES) and RNA-sequencing (RNA-seq) of tumors harvested through one responder’s treatment was performed. With a median follow up of 119 days, patients treated with Ipi10 + TMZ had a statistically significant longer median progression-free survival of 144.5 days (range 27–219) vs. 44 (26–75) in Ipi 3 mg/kg (Ipi3) + TMZ, p = 0.04, and a trend of longer median overall survival of 154.5 days (27–537) vs. 89.5 (26–548). Two patients in the Ipi10 + TMZ cohort had a partial response, and both responders had BRAF V600E mutant melanoma. RNA-seq showed enrichment of inflammatory signatures, including interferon responses in metastases after Ipi10 + TMZ compared to the primary tumor, and downregulated negative immune regulators. Ipi10 + TMZ demonstrated efficacy, including dramatic responses in patients refractory to prior Ipi + anti-PD1. Molecular data suggest a potential threshold of Ipi dose for activation of sufficient anti-tumor immune response, and higher doses are required for some patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaIpilimumabTemozolomideAntineoplastic Combined Chemotherapy ProtocolsSkin NeoplasmsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultDisease Progression

Stichwörter der Autor:innen

advanced melanomaimmune checkpoint inhibitorsmolecular profilingrefractory melanomatranslational research

Substanzen

IpilimumabTemozolomide

Autor:innen und Institutionen

  • Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, UT 84112, USA.
  • Huntsman Cancer Institute, Salt Lake City, UT 84112, USA.
  • Intermountain Health, Murray, UT 84107, USA.

ORCID-Profile: Julie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, Umang Swami, Tawnya L Bowles, Jordan McPherson, Aik-Choon Tan

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health (NIH)
  • Huntsman Cancer Institute at the University of Utah Cancer Center Support

Zitieren

APA

Williamson, J., Fadlullah, M. Z. H., Kovacsovics-Bankowski, M., Gibson, B., Swami, U., Erickson-Wayman, A., Jamison, D., Sageser, D., Jeter, J., Bowles, T. L., Cannon, D. M., Haaland, B., Schroeder, J. D., Nix, D. A., Atkinson, A., Hyngstrom, J., McPherson, J., Tan, A. C., & Hu-Lieskovan, S. (2025). Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma. Current Oncology. https://doi.org/10.3390/curroncol32030144

Vancouver

Williamson J, Fadlullah MZH, Kovacsovics-Bankowski M, Gibson B, Swami U, Erickson-Wayman A, et al. Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma. Current Oncology. 2025. doi:10.3390/curroncol32030144

BibTeX
@article{Williamson2025,
  author = {Williamson, Julie and Fadlullah, Muhammad Zaki Hidayatullah and Kovacsovics-Bankowski, Magdalena and Gibson, Berit and Swami, Umang and Erickson-Wayman, Alyssa and Jamison, Debra and Sageser, Dan and Jeter, Joanne and Bowles, Tawnya L and Cannon, Donald M and Haaland, Ben and Schroeder, Joyce D and Nix, David A and Atkinson, Aaron and Hyngstrom, John and McPherson, Jordan and Tan, Aik-Choon and Hu-Lieskovan, Siwen},
  title = {Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32030144}
}
Kostenlos starten →